Skip to main content

Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022

Written by Customer Service on . Posted in Public Companies.

Basel, Switzerland, June 30, 2020
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a lease agreement for office space and laboratories at the new innovation park GRID, which is currently being built by SENN Resources AG in Allschwil, in the canton of Basel-Landschaft. Basilea plans to move to its new corporate headquarters at the GRID in mid-2022.David Veitch, Chief Executive Officer, said: “Following the recent sale of our current corporate headquarter property, we are excited to now take the next important step towards moving the Basilea team, currently working at different locations across Basel, into one place. We will benefit from the close proximity to innovative start-up companies, academic institutions and other biotech companies in the emerging life sciences and technology cluster. Additionally, we expect a positive impact on our operating and capital expenses from this move.”About GRIDBordering on Basel City, the GRID (Grand Réseau d’Innovation et de Développement) is a new 50,000 m2 cornerstone in the booming biotech cluster of Allschwil, home to institutions like the Swiss Tropical and Public Health Institute and life sciences companies like Abbott, Actelion, and Idorsia and deemed to become one of Switzerland’s most important life sciences ecosystems. The new landmark campus-style building was developed by SENN and designed by Herzog & de Meuron architects, with Switzerland Innovation Park Basel Area and the University of Basel as direct neighbours.About BasileaBasilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea’s website www.basilea.com. DisclaimerThis communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.For further information, please contact:This press release can be downloaded from www.basilea.com. AttachmentPress release (PDF)

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.